Home Lilly Acquires Injectable Drug Manufacturing Facility to Address GLP-1 Capacity Constraints Amid Intensifying Rivalry with Novo Nordisk

Lilly Acquires Injectable Drug Manufacturing Facility to Address GLP-1 Capacity Constraints Amid Intensifying Rivalry with Novo Nordisk

Apr 27, 2024 12:54 CST Updated 12:54
Eli Lilly

Global Pharmaceutical R&D and Production Company

Nexus Pharmaceuticals

Specialty Drug Developer